Eloxx Pharmaceuticals ( (ELOX) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eloxx Pharmaceuticals has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The primary reason for this delay is the company’s ongoing financial constraints, which have prevented it from engaging an independent public accounting firm to review its unaudited financial statements. Eloxx Pharmaceuticals has not provided a specific timeline for when the delayed report will be filed. The company has indicated that there will be significant changes in its financial results, including an increase in net loss and accumulated deficit for the first quarter of 2025 compared to the same period in 2024. Additionally, there is substantial doubt about the company’s ability to continue as a going concern due to insufficient cash resources. The notification was signed by Sumit Aggarwal, President and CEO, on May 15, 2025, as part of the company’s ongoing compliance efforts.
More about Eloxx Pharmaceuticals
Average Trading Volume: 225
Technical Sentiment Signal: Strong Sell
Current Market Cap: $314
Find detailed analytics on ELOX stock on TipRanks’ Stock Analysis page.